Topics:

Hematologic Malignancies

Hematologic Malignancies

The rationale for maintenance therapy in indolent non-Hodgkin lymphoma was derived from historical data suggesting that despite robust response rates to standard therapy, most patients eventually relapse and disease-free intervals become progressively shorter.

While definitions of follicular lymphoma maintenance therapy in clinical trials and clinical practice have been somewhat variable, ideally maintenance therapy would be limited to patients in complete remission or with minimal residual disease following initial therapy

The optimal treatment strategy for newly diagnosed multiple myeloma is consolidation with melphalan, stem-cell transplantation, then lenalidomide maintenance.

Continuous treatment with lenalidomide plus dexamethasone improved progression-free and overall survival in transplant-ineligible multiple myeloma patients.

STAT3 inhibition using a novel compound restored sensitivity to TKIs in CML cells that had shown resistance independent of BCR-ABL1 kinase activity.

A laboratory study found that natural killer cells could be multiplied from the blood of patients to fight off precursor B-lineage acute lymphoblastic leukemia.

Survivors of Hodgkin lymphoma may be at increased risk of diabetes if they were exposed to radiation to the para-aortic lymph nodes and spleen during treatment.

Pages

Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.